Potential Ulcerative Colitis Therapy Advancing in Clinical Development

Potential Ulcerative Colitis Therapy Advancing in Clinical Development
Tiziana Life Sciences recently announced its plan for further development of foralumab, the company’s fully human anti-CD3 antibody, with a first evaluation of the compound in two clinical indications: graft vs. host disease, and ulcerative colitis, an inflammatory bowel disease (IBD). Foralumab is the only fully human engineered anti-CD3 antibody currently in clinical development, the company reports.

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. redouane says:

    Digging deeper into my thoughts, I found that I was wanting to express this gratitude I am feeling for those who have lost their battle to ALS. I am saddened that anyone had to lose their life to this nasty disease and it pains me that so many suffered a horrible fight and continue to this day to loose to this battle. I want to give thanks to all the amazing and courageous fighters that have faced this disease head on, who endured so much and gave a strong fight to the end. These people paved the way for all of us now who are getting cured…including myself.
    i was been cured of ALS from a man, i would love you’ll to meet he is nice and he got me cure within the period of 3 months, here is his mail [email protected]

Leave a Comment

Your email address will not be published. Required fields are marked *